

Lymphoma Research Foundation



115 Broadway, Suite 1301
New York, NY 10006
(212) 349-2910
www.lymphoma.org



Mission

The Lymphoma Research Foundation (LRF) is the nation's largest nonprofit organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF's mission is to eradicate lymphoma and serve those touched by the disease.

Strategy/Approach

LRF's programs seek to change the future for everyone whose life has been affected by a lymphoma diagnosis. It:

- Funds biomedical research focused on the origins, treatment, and identification of a cure for lymphoma;
- Raises public awareness of the disease; and
- Provides support and services to people with lymphoma, their families, and caregivers.

The LRF **Advocacy Program** provides volunteers with the tools necessary to garner attention and support for those public policies most important to the lymphoma community. Advocates focus on increasing federal investment in lymphoma research, ensuring access to lymphoma treatment and survivorship care, maintaining and protecting federal support for blood cancer education programs, and supporting access for lymphoma patients to clinical research studies.

LRF provides a variety of programs and services to more than 35,000 people impacted by lymphoma each year. These include a clinical trials information service, lymphoma helpline, support network, disease-specific educational resources, and advocacy program. The foundation also offers education and support to physicians, nurses, and social workers to increase their knowledge and skills for the benefit of lymphoma patients.

Research Portfolio

LRF's research portfolio extends to all lymphoma subtypes and consists of the following funding opportunities:

- **Clinical Investigator Career Development Awards**
 - **Post-Doctoral Fellowships** – Help attract researchers to the field of lymphoma and allow them to pursue promising leads under the guidance of a sponsor.
 - \$50,000 in year one and \$55,000 in year two
 - **Clinical Investigator Career Development Awards** – Fund training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma.
 - Up to \$75,000/year for three years
 - **Clinical Research Mentoring Program**—for advanced doctoral fellows and junior faculty. A

select group of LRF scholars to receive mentoring and education dedicated to all aspects of clinical research.

- *Includes a mini-grant of \$5,000 per year for up to two years to cover travel, conference fees, and other activities that further career development*
- **Disease-Specific Research Initiatives**
 - **Chronic Lymphocytic Leukemia (CLL) Initiative** – Aims to develop novel therapeutic strategies for the treatment of CLL/SLL by funding projects that advance the understanding of the human biology of this disease and/or that verify molecular targets for CLL/SLL therapeutics. In 2006-2007, funding was available for up to three years, for a maximum of \$250,000 per year.
 - **Diffuse Large B-Cell Lymphoma (DLBCL) Explorations Grant**—funding the study of primary DLBCL patient samples between/among investigators of different disciplines.
 - Up to \$125,000 per year for two years
 - **Follicular Lymphoma (FL) Initiative and Consortium** – Aims to develop novel therapeutic strategies for the treatment of FL. Offers an FL pathways grant, which supports research that advances the understanding of the human biology of FL or verifies molecular targets for FL therapeutics, and an FL Correlative Clinical Studies Award.
 - *Pathway Grant* – \$250,000/year for three years
 - *Correlative Clinical Studies Award* – \$125,000/year for three years
 - **Mantle Cell Lymphoma (MCL) Initiative and Consortium** – Formed in 2003, it aims to accelerate the pace of research in MCL, which accounts for about 6 percent of all non-Hodgkin lymphoma. It has awarded \$23.5 million to support 47 research grants. LRF-funded MCL research projects have ranged from laboratory studies to the identification of new therapeutic approaches, including clinical trials of novel agents, chemo immunotherapy, radiation therapy, and stem cell transplantation. Previously, funding for this initiative has been up to \$250,000 for up to three years.
 - **Diffuse Large B-Cell Lymphoma (DLBCL) Collaborative Grant** – Created to fund high-quality research studies in DLBCL, including the study of primary DLBCL patient samples. These grants aim to advance understanding of DLBCL

and key areas such as host tumor interactions, key biologic features, and drug resistance.

➤ \$125,000/year for two years

Partnership Practices

LRF partners with biotech and pharmaceutical companies, along with a variety of businesses, to help advance its mission.

LRF bestows **Corporate Leadership Awards** to private companies that display “exemplary leadership in the oncology business community.” The recipients of this award demonstrate a commitment to the foundation and its mission. For example, 2010 winner **Allos Therapeutics** worked with LRF over several years as both a partner and a sponsor to provide services to the lymphoma community. In addition to supporting foundation programs and helping to grow the LRF research portfolio, it was also a key partner in the T-Cell Lymphoma Consortium and LRF’s professional education initiatives.

LRF also engages in traditional corporate sponsorships (e.g., Genentech, Novartis, Celgene, Millennium, Spectrum Pharmaceuticals, Inc., Cephalon Oncology, and Merck & Co., Inc.).

Financials


The foundation is a 501(c)(3) charitable organization. The most recent financial information available is from FY2013.¹

Year ending 6/30/2013:

- Revenue: \$10,407,095
- Assets: \$14,110,108
- Gifts Received: \$5,231,461
- Expenditures: \$10,974,664
- Program services: \$8,716,932
- Supporting services: \$2,257,732

Key Accomplishments

2013 Expenses



- LRF has funded more than \$51 million in lymphoma research in the United States, Canada, and Europe.

- In FY 2012, LRF awarded \$3.7 million in research grants.
- The MCL Research Grants program alone has awarded \$23.5 million to support 47 research grants.
- Through patient programs and services, LRF reaches more than 35,000 members of the lymphoma community.
- LRF has 18 chapters that serve the lymphoma community.
- In 2011, LRF provided more than 20,000 health professionals with educational materials on advancements in the field of lymphoma.
- A clinical trial co-led by LRF Scientific Advisory Board members found that targeted drug ibrutinib may benefit some patients with diffuse large B-cell lymphoma.
- Created **Focus on Lymphoma**, a mobile health app as a comprehensive solution for patients, caregivers, and healthcare specialists. Contains up-to-date blood cancer information as well as advanced tools to help patients manage their lymphoma and optimize time spent with healthcare providers.

Leadership

The foundation is primarily led by a **Board of Directors** and a **Scientific Advisory Board**.

- **CEO:** Elizabeth Thompson, ethompson@lymphoma.org
- **Chief Program, Policy, & Communications Officer:** Meghan Gutierrez, mgutierrez@lymphoma.org
- **Chief Program Officer:** Brian Tomlinson, btomlinson@lymphoma.org

¹ Information obtained from LRF Audited Financial Statement for 2013. <http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6478875>